GeneDx Holdings Dirección
Dirección controles de criterios 3/4
El CEO de GeneDx Holdings es Katherine Stueland , nombrado en May 2022, tiene una permanencia de 2.5 años. compensación anual total es $3.58M, compuesta por 18.9% salario y 81.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.22% de las acciones de la empresa, por valor de $4.72M. La antigüedad media del equipo directivo y de la junta directiva es de 1.1 años y 3.3 años, respectivamente.
Información clave
Katherine Stueland
Chief Executive Officer (CEO)
US$3.6m
Compensación total
Porcentaje del salario del CEO | 18.9% |
Permanencia del CEO | 2.5yrs |
Participación del CEO | 0.2% |
Permanencia media de la dirección | 1.1yrs |
Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce
Nov 23US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results
Nov 01GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
Oct 30GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
Oct 21After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar
Oct 04Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
Aug 19Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher
Jul 27GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors
Jun 12GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
Jun 06Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13
Feb 23The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More
Feb 22Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified
Dec 20Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)
Nov 02Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%
Nov 01Sema4 names Kevin Feeley as CFO
Aug 26Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Aug 20Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 19Sema4 Q2 2022 Earnings Preview
Aug 12Sema4 Holdings, Big Data For Precision Medicine Solutions
Jul 18Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$83m |
Jun 30 2024 | n/a | n/a | -US$117m |
Mar 31 2024 | n/a | n/a | -US$135m |
Dec 31 2023 | US$4m | US$675k | -US$176m |
Sep 30 2023 | n/a | n/a | -US$459m |
Jun 30 2023 | n/a | n/a | -US$494m |
Mar 31 2023 | n/a | n/a | -US$533m |
Dec 31 2022 | US$12m | US$454k | -US$549m |
Compensación vs. Mercado: La compensación total de Katherine($USD3.58M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.54M).
Compensación vs. Ingresos: La compensación de Katherine ha sido consistente con los resultados de la empresa en el último año.
CEO
Katherine Stueland (48 yo)
2.5yrs
Permanencia
US$3,575,335
Compensación
Ms. Katherine A. Stueland serves as Chief Executive Officer & Director at GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp.) since May 2022 and serves as its President. She served as President...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 2.5yrs | US$3.58m | 0.22% $ 4.7m | |
Chief Financial Officer | 2.3yrs | US$1.57m | 0.16% $ 3.5m | |
Head of Operations | 1.1yrs | sin datos | sin datos | |
Chief Product & Technology Officer | less than a year | sin datos | sin datos | |
Head of People Strategy | less than a year | sin datos | sin datos | |
Chief Medical Officer | 2.5yrs | sin datos | sin datos | |
Chief Growth Officer | 1.2yrs | sin datos | sin datos | |
Chief of Staff | no data | sin datos | sin datos | |
Head of Medical Affairs | less than a year | sin datos | sin datos |
1.1yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de WGS no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 2.5yrs | US$3.58m | 0.22% $ 4.7m | |
Independent Director | 7yrs | US$162.00k | 0.71% $ 15.3m | |
Director | 2.6yrs | US$147.00k | 0.10% $ 2.2m | |
Independent Director | 2.8yrs | US$162.00k | 0.026% $ 567.2k | |
Independent Director | 4.3yrs | US$154.50k | 0.028% $ 597.7k | |
Chairman of the Board | 3.3yrs | US$992.46k | 0.53% $ 11.5m | |
Independent Director | 4.2yrs | US$160.75k | 0.030% $ 657.3k |
3.3yrs
Permanencia media
50.5yo
Promedio de edad
Junta con experiencia: La junta directiva de WGS se considera experimentada (3.3 años de antigüedad promedio).